HNGE vs SYRE
Hinge Health, Inc. vs Spyre Therapeutics, Inc. — AI-powered side-by-side comparison
HNGE
Hinge Health, Inc.
64
Buy
VS
SYRE
Spyre Therapeutics, Inc.
68
Buy
| Metric | HNGE | SYRE |
|---|
| AI Score |
64
|
68
|
| Price |
$86.36
|
$104.13
|
| P/E Ratio |
66.10×
|
-52.69×
|
| ROE |
-139.6%
|
-21.7%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
84.5%
|
0.0%
|
| Debt / Equity |
0.02×
|
0.00×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
69.6
|
53.3
|
| Beta |
1.285
|
3.026
|
| Expected Upside |
—
|
—
|
AI Committee View
Current Innellis committee reasoning for HNGE versus SYRE.
SYRE leads by 4 points.
SYRE scores 68/100 (Buy) versus HNGE at 64/100 (Buy).
HNGE Committee View
67% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- Price-to-book of 9.7x prices in significant intangible value — Value
- ROE of only -138.7% -- cheap may mean cheap for a reason — Value
- Bollinger bandwidth of 28.9% signals elevated volatility — Risk
SYRE Committee View
83% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
Bear Case
- ROE of only -24.3% -- cheap may mean cheap for a reason — Value
- MACD histogram negative -- bearish momentum — Technical
- Weekly RSI at 77 -- overbought on the larger timeframe too — Technical